Your AI-Trained Oncology Knowledge Connection!
Video
Author(s):
Jennifer A. Stein, MD, PhD, an associate professor of dermatology at New York University School of Medicine in New York, discusses the skin-related adverse events (AEs) associated with melanoma treatment.
Jennifer A. Stein, MD, PhD, an associate professor of dermatology at New York University School of Medicine in New York, discusses the skin-related adverse events (AEs) associated with melanoma treatment.
Patients can develop AEs with immunotherapies such as ipilimumab (Yervoy), nivolumab (Opdivo), and pembrolizumab (Keytruda), and there is a set of AEs they can get with the BRAF inhibitors. The most common AE with checkpoint inhibitors, for all organs, is rash. It is often fairly mild, and it can usually be treated with topical steroids or oral antihistamines, Stein explains. More severe but rare AEs include bullous pemphigoid, Stevens-Johnson syndrome, or toxic epidermal necrolysis.
There are severe allergic reactions in which the skin starts to blister and actually peel off, Stein adds. While they can be life-threatening, they are pretty rare.
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 6th 2025 - Jul 12th 2025
Jun 6th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 6th 2025 - Jul 12th 2025
Jun 6th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Venetoclax/DEC-C Is Potential New SOC in Newly Diagnosed AML Ineligible for Intensive Chemo
Revumenib-Based Triplet Is Safe, Highly Active in Older/Unfit NMP1/KMT2A-Altered AML
Dr Skrypets on an Analysis of Clinical Features of Older Patients With PTCL
Olaparib/Temozolomide Fails to Meet PFS End Point in Previously Treated Advanced Uterine Leiomyosarcoma
2 Commerce Drive
Cranbury, NJ 08512